Trials / Completed
CompletedNCT00764946
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female, either having received antiretroviral drugs before or not.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comparator: raltegravir | 400 mg tablets taken twice daily. Total treatment period is 48 weeks. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2008-10-02
- Last updated
- 2017-03-21
- Results posted
- 2012-04-12
Source: ClinicalTrials.gov record NCT00764946. Inclusion in this directory is not an endorsement.